Literature DB >> 9856846

An atypical form of bullous congenital ichthyosiform erythroderma is caused by a mutation in the L12 linker region of keratin 1.

H Kremer1, A P Lavrijsen, W H McLean, E B Lane, D Melchers, D J Ruiter, E C Mariman, P M Steijlen.   

Abstract

Defective keratins are the cause of a number of hereditary disorders of the epidermis and other epithelia. The disease-causing mutations in keratins are clustered in the rod domain, and mutations in the helix boundary peptides cause the most severe forms of epidermal fragility syndromes. Siemens described a family with an atypical, mild form of bullous congenital ichthyosiform erythroderma. Linkage analysis in this family indicated that a defective type II keratin might be the underlying cause, keratins K1 and K2e being the best candidates. A substitution of valine for aspartic acid was detected at position 340 (D340V) in the L12 region of the K1 polypeptide. The mutation was found to cosegregate with the disorder in the family. Herewith, a genotype-phenotype correlation is shown for bullous congenital ichthyosiform erythroderma comparable with that described for epidermolysis bullosa simplex.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9856846     DOI: 10.1046/j.1523-1747.1998.00389.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  3 in total

Review 1.  Ichthyosis update: towards a function-driven model of pathogenesis of the disorders of cornification and the role of corneocyte proteins in these disorders.

Authors:  Matthias Schmuth; Robert Gruber; Peter M Elias; Mary L Williams
Journal:  Adv Dermatol       Date:  2007

2.  Regulation of keratin expression by retinoids.

Authors:  Hans Törmä
Journal:  Dermatoendocrinol       Date:  2011-07-01

3.  A novel arginine substitution mutation in 1A domain and a novel 27 bp insertion mutation in 2B domain of keratin 12 gene associated with Meesmann's corneal dystrophy.

Authors:  M K Yoon; J F Warren; D S Holsclaw; D C Gritz; T P Margolis
Journal:  Br J Ophthalmol       Date:  2004-06       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.